Alterations to haemostasis following cardiopulmonary bypass and the relationship of these changes to neurocognitive morbidity

Blood Coagulation and Fibrinolysis

Volumn 12, Issue 8, 2001, Pages 601-618

  Raymond, P D ^a   Marsh, N A ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Brain; Cardiopulmonary bypass; Coagulation; Haemostasis; Microemboli; Neuropsychological dysfunction; Stroke; Tissue factor

Indexed keywords

BLOOD CLOTTING; BRAIN INJURY; BRAIN ISCHEMIA; CARDIOPULMONARY BYPASS; COGNITIVE DEFECT; FIBRIN FORMATION; FIBRINOLYSIS; HEART SURGERY; HEMOSTASIS; HUMAN; MICROEMBOLISM; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOEMBOLISM; BLOOD; CEREBROVASCULAR DISEASE; INCIDENCE; METHODOLOGY; PHYSIOLOGY; STANDARD;

CARDIOPULMONARY BYPASS; CEREBROVASCULAR DISORDERS; COGNITION DISORDERS; HEMOSTASIS; HUMAN; INCIDENCE; INTRACRANIAL EMBOLISM AND THROMBOSIS;

EID: 0035205883     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200112000-00001     Document Type: Review

References (149)

1. Historical aspects of cardiopulmonary bypass: From antiquity to acceptance
2. Historical development of cardiopulmonary bypass
3. Perfusion safety: Past, present, and future
4. Psychological disturbances associated with open heart surgery
5. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment-F(1 + 2)
6. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin
7. Changes in coagulation and fibrinolytic parameters caused by extracorporeal circulation
8. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers
9. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass
10. Monitoring thrombin generation with prothrombin fragment 1 + 2 assay during cardiopulmonary bypass surgery
11. Elevated plasma fibrinopeptide A and thromboxane B2 levels during cardiopulmonary bypass
12. Maintenance of homeostasis in coagulation during cardiopulmonary bypass
13. Studies on components of the plasma kallikreinkinin system in patients undergoing cardiopulmonary bypass
14. 2-plasmin-inhibitor complexes during cardiopulmonary bypass
15. Adsorption of Hageman factor (factor XII) and other human plasma proteins to biomedical polymers
16. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass
17. FXII levels, FXIIa-like activities and kallikrein activities in normal subjects and patients undergoing cardiac surgery
18. An ELISA for factor X activation peptide - Application to the investigation of thrombogenesis in cardiopulmonary bypass
19. The tissue factor pathway -how it has become a prima ballerina
20. Cell biology of tissue factor, the principal initiator of blood coagulation
21. Cardiopulmonary bypass. Associated hemostatic abnormalities
22. Haemostatic changes in the pulmonary blood during cardiopulmonary bypass
23. The role of tissue factor pathway inhibitor in a revised coagulation cascade
24. Tissue factor pathway inhibitor and the current concept of blood coagulation
25. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor
26. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations
27. The effect of heparin and its neutralisation on functional assays for factor VIIa, factor VII and TFPI
28. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation
29. Two-chain factor VIIa generated in the pericardium during surgery with cardiopulmonary bypass - Relationship to increased thrombin generation and heparin concentration
30. Platelet activation and cytokine production during hypothermic cardiopulmonary bypass - A possible correlation
31. Inflammatory response after myocardial revascularization with or without cardiopulmonary bypass
32. Cardiopulmonary bypass-induced inflammation: Is it important?
33. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass
34. Release of lipopolysaccharide toxicity-modulating proteins in patients undergoing cardiopulmonary bypass using noncoated and heparin-coated extracorporeal circuits - A clinical pilot study
35. Down-regulation of surface monocyte lipopolysaccharide-receptor CD14 in patients on cardiopulmonary bypass undergoing aorta-coronary bypass operation
36. Tissue factor is expressed on monocytes during simulated extracorporeal circulation
37. Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass - A clinical study
38. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass
39. Direct activation of factor X by monocytes occurs during cardiopulmonary bypass
40. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass
41. Increased coagulation and bradykinin-release in shed pleural blood during cardiac surgery
42. Tissue factor is rapidly elevated in plasma collected from the pericardial cavity during cardiopulmonary bypass
43. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant
44. Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism
45. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
46. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor factor Xa-induced inhibition of factor VIIa/tissue factor activity
47. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation
48. Heparin and antithrombin III levels during cardiopulmonary bypass: Correlation with subclinical plasma coagulation
49. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols
50. Adequate anti-coagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer
51. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass
52. Monitoring heparin during cardiopulmonary bypass (CPB) surgery using three commercial instruments - Hepcon HMS, Hemochron ACT and HemoTec ACT
53. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations
54. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather then ACT
55. Maintenance of blood heparin concentration rather than activated clotting time better preserves the coagulation system in hypothermic cardiopulmonary bypass
56. The impact of heparin concentration and activated clotting time monitoring on blood conservation - A prospective, randomized evaluation in patients undergoing cardiac operation
57. Hemostasis management by use of Hepcon/ HMS™: Increased bleeding without increased need for blood transfusion
58. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients
59. Aprotinin - A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery
60. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin
61. Aprotinin inhibits thrombin formation and monocyte tissue factor in simulated cardiopulmonary bypass
62. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion
63. Hemostasis in patients undergoing extracorporeal circulation: The effect of aprotinin (Trasylol)
64. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery -a double-blind, placebo-controlled study
65. Does aprotinin influence endothelial-associated coagulation in cardiac surgery?
66. Inhibition of coagulation and fibrinolysis by aprotinin in patients undergoing cardiopulmonary bypass surgery
67. A pump-prime aprotinin dose in cardiac surgery - Appraisal of its effects on the hemostatic system
68. The antithrombotic effect of aprotinin: Actions mediated via the protease-activated receptor 1
69. Factor XI and protection of the fibrin clot against lysis: A role for the intrinsic pathway of coagulation in fibrinolysis
70. Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass
71. Elevated fibrinolysis in cardiopulmonary bypass is factor XII dependent
72. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III
73. Neurological complications of coronary revascularization
74. Stroke following coronary artery bypass grafting: A ten-year study
75. Cerebral complications after coronary artery bypass and heart valve surgery -risk factors and onset of symptoms
76. Neurological complications after cardiopulmonary bypass: An update
77. Perioperative stroke in coronary artery bypass surgery - Analysis of risk factors
78. Intraoperative physiologic variables and outcome in cardiac surgery: Part II. Neurologic outcome
79. Central nervous system complications of coronary artery bypass graft surgery: Prospective analysis of 421 patients
80. Adverse cerebral outcomes after coronary bypass surgery
81. Stroke in cardiac surgical patients: Determinants and outcome
82. Early neurological complications of coronary artery bypass surgery
83. Neurologic and neuropsychological morbidity following major surgery: Comparison of coronary artery bypass and peripheral vascular surgery
84. Neuropsychological disorders after coronary bypass surgery
85. Arterial line filtration during cardiopulmonary bypass. Neurologic, neuropsychologic, and hematologic studies
86. Brain SPECT imaging and neuropsychological testing in coronary artery bypass patients
87. Jugular bulb saturation and cognitive dysfunction after cardiopulmonary bypass
88. Neuromonitoring and neurocognitive outcome in off-pump versus conventional coronary bypass operation
89. Patient memory before and after cardiac operations
90. Cognitive outcome after coronary artery bypass: A one-year prospective study
91. Preliminary findings of neurocognitive and neurological morbididty after cardiopulmonary bypass (CPB)
92. Neuropsychologic changes after coronary artery bypass grafting: Use of reliable change indices
93. Defining neuropsychological dysfunction after coronary artery bypass grafting
94. Graded neurological scale for use in acute hemisphere stroke treatment protocols
95. Statement of consensus on assessment of neurobehavioral outcomes after cardiac surgery
96. Brain damage during cardiopulmonary bypass
97. The inflammatory response to cardiopulmonary bypass
98. The inflammatory response and extra-corporeal circulation
99. Complement and the damaging effects of cardiopulmonary bypass
100. Brain swelling in first hour after coronary artery bypass surgery
101. Cardiopulmonary bypass and the blood - Brain barrier. An experimental study
102. Intraoperative embolus formation during cardiopulmonary bypass affects the release of S100B
103. Cerebral blood flow and metabolism during cardiopulmonary bypass
104. Cerebrovascular and cerebral metabolic effects of alterations in perfusion flow rate during hypothermic cardiopulmonary bypass in man
105. Experimental study of cerebral autoregulation during cardiopulmonary bypass with or without pulsatile perfusion
106. Effect of perfusion pressure on cerebral blood flow during normothermic cardiopulmonary bypass
107. Effect of pump flow rate on cerebral blood flow during hypothermic cardiopulmonary bypass in adults
108. + at critical levels of brain ischemia
109. Hypothermic modulation of cerebral ischemic injury during cardiopulmonary bypass in pigs
110. Cerebral oxygenation is better during mild hypothermic than normothermic cardiopulmonary bypass
111. Cerebral physiology in paediatric cardiopulmonary bypass
112. The role of CPB management in neurobehavioral outcomes after cardiac surgery
113. Normothermic versus hypothermic cardiopulmonary bypass: Central nervous system outcomes
114. Effect of mild hypothermia on ischemia-induced release of neurotransmitters and free fatty acids in rat brain
115. Determinants of cerebral perfusion during cardiopulmonary bypass
116. 2
117. Conduct and monitoring of cardiopulmonary bypass
118. Effect of differing acid-base regulation on cerebral blood flow autoregulation during cardiopulmonary bypass
119. Relative changes in cerebral blood flow during cardiac operations using Xenon-133 clearance versus transcranial doppler sonography
120. Acid-base management during hypothermic cardiopulmonary bypass does not affect cerebral metabolism but does affect blood flow and neurological outcome
121. Hypothermic acid - Base management does not affect cerebral metabolic rate for oxygen at 27°C - A study during cardiopulmonary bypass in rabbits
122. A randomized study of the influence of perfusion technique and pH management strategy in 316 patients undergoing coronary artery bypass surgery. II. Neurologic and cognitive outcomes
123. Hyperperfusion and cerebral dysfunction: Effect of differing acid - Base management during cardiopulmonary bypass
124. Cardiopulmonary bypass: Perioperative cerebral blood flow and post-operative cognitive deficit
125. Alpha-stat acid-base regulation during cardiopulmonary bypass improves neuropsychologic outcome in patients undergoing coronary artery bypass grafting
126. 2
127. Embolic events and cardiopulmonary bypass
128. Gaseous microemboli: Sources, causes, and clinical considerations
129. Two membrane oxygenators and a bubbler: A clinical comparison
130. A clinical evaluation of the performance characteristics of one membrane and five bubble oxygenators: Gas transfer and gaseous microemboli production
131. The detection of microemboli in the middle cerebral artery during cardiopulmonary bypass: A transcranial Doppler ultrasound investigation using membrane and bubble oxygenators
132. Cardiotomy suction - A major source of brain lipid emboli during cardiopulmonary bypass
133. Capture of particulate emboli during cardiac procedures in which aortic cross-clamp is used
134. Craniocervical and aortic atherosclerosis as neurologic risk factors in coronary surgery
135. Protruding aortic atheromas predict stroke in elderly patients undergoing cardiopulmonary bypass: Experience with intraoperative transesophageal echocardiography
136. Atherosclerosis of the ascending aorta and coronary artery bypass. Pathology, clinical correlates, and operative management
137. Ultrasonographic demonstration of manipulation-related aortic injuries after cardiac surgery
138. The platelet in cardiopulmonary bypass
139. Perioperative stroke. Part II: Cardiac surgery and cardiogenic embolic stroke
140. Cerebral microembolism during cardiopulmonary bypass. Retinal microvascular studies in vivo with fluorescein angiography
141. Neuropathologic complications of cardiac surgery
142. Posterior distribution of infarcts in strokes related to cardiac operations
143. Mechanism of stroke complicating cardiopulmonary bypass surgery
144. Impact of embolization during coronary artery bypass grafting on outcome and length of stay
145. Risk factors and solutions for the development of neurobehavioral changes after coronary artery bypass grafting
146. Microemboli during coronary artery bypass grafting - Genesis and effect an outcome
147. Cerebral emboli detected during bypass surgery are associated with clamp removal
148. Aprotinin: Safe and effective only with the full-dose regimen